Hypoxia: A Double-Edged Sword in Cancer Therapy

Targeting HIF-1 for cancer therapy

Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717

Targeting hypoxia in cancer therapy

Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172

Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166

Role of oxygen radicals in DNA damage and cancer incidence

Valko, M., Izakovic, M., Mazur, M., Rhodes, C. J., & Telser, J. (2004) · Molecular and Cellular Biochemistry · doi:10.1023/b:mcbi.0000049134.69131.89 · Cited by 1,820

Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer

Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,777

The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,499

DNA Damage Produced by Ionizing Radiation in Mammalian Cells: Identities, Mechanisms of Formation, and Reparability

Ward, J. F. (1988) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60611-x · Cited by 1,499

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314

Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response

McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050

Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues

Murdoch, C., Giannoudis, A., & Lewis, C. E. (2004) · Blood · doi:10.1182/blood-2004-03-1109 · Cited by 911

Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response

Vaupel, P., & Harrison, L. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90005-4 · Cited by 761

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF

Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00077-1 · Cited by 730

Detection and Characterization of Tumor Hypoxia Using pO 2 Histography

Vaupel, P., Höckel, M., & Mayer, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1628 · Cited by 728

Hypoxia and hypoxia-inducible factors: master regulators of metastasis

Lu, X., & Kang, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1360 · Cited by 723

Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway

Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663

Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression

Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 657

Macrophage Expression of Hypoxia-Inducible Factor-1α Suppresses T-Cell Function and Promotes Tumor Progression

Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W., & Johnson, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1439 · Cited by 652

Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways

Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 628

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

Overgaard, J., Hansen, H. S., Overgaard, M., Bastholt, L., Berthelsen, A., Specht, L., Lindeløv, B., & Jørgensen, K. J. (1998) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(97)00220-x · Cited by 575

Treatment Resistance of Solid Tumors

Vaupel, P. W., Thews, O., & Hoeckel, M. (2001) · Medical Oncology · doi:10.1385/mo:18:4:243 · Cited by 571

Suppression of tumor growth through disruption of hypoxia-inducible transcription

Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., & Livingston, D. M. (2000) · Nature Medicine · doi:10.1038/82146 · Cited by 502

Role of hypoxia in the hallmarks of human cancer

Ruan, K., Song, G., & Ouyang, G. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22214 · Cited by 493

Untitled work

(2002) · PubMed · Cited by 457

Hypoxia-driven selection of the metastatic phenotype

Sullivan, R., & Graham, C. H. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9062-2 · Cited by 423

Tumor hypoxia: A target for selective cancer therapy

Kizaka‐Kondoh, S., Inoue, M., Harada, H., & Hiraoka, M. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01395.x · Cited by 356

Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies

Brown, J. M. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01677-4 · Cited by 352

Bacteria in cancer therapy: a novel experimental strategy

Patyar, S., Joshi, R., Byrav, D. P., Prakash, A., Medhi, B., & Das, B. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-21 · Cited by 343

Hypoxia‐inducible factors in regulation of immune responses in tumour microenvironment

Kumar, V., & Gabrilovich, D. I. (2014) · Immunology · doi:10.1111/imm.12380 · Cited by 329

Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells.

Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Meir, E. G. V., Simons, J. W., & Zhong, H. (2002) · PubMed · Cited by 299

Negative and positive regulation of HIF-1: A complex network

Bárdos, J. I., & Ashcroft, M. A. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.05.001 · Cited by 287

Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents

Braun, R. D., Lanzen, J. L., Snyder, S. A., & Dewhirst, M. W. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.280.6.h2533 · Cited by 285

Development of a hypoxia-responsive vector for tumor-specific gene therapy

Shibata, T., Giaccia, A. J., & Brown, J. M. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301124 · Cited by 267

Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery

Renfrew, A. K. (2014) · Metallomics · doi:10.1039/c4mt00069b · Cited by 252

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs

Phillips, R. M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2920-7 · Cited by 248

Hypoxia‐inducible factor‐1α contributes to hypoxia‐induced chemoresistance in gastric cancer

Liu, L., Ning, X., Sun, L. J., Zhang, H., Shi, Y., Guo, C., Han, S., Liu, J., Sun, S., Han, Z., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00643.x · Cited by 230

Targeting hypoxia cell signaling for cancer therapy

Melillo, G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9059-x · Cited by 230

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

Meng, F., Evans, J., Bhupathi, D., Banica, M., Lan, L., Lorente, G., Duan, J.-X., Cai, X., Mowday, A. M., Guise, C. P., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0634 · Cited by 205

Clostridia in cancer therapy

Minton, N. P. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro777 · Cited by 197

Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis

Liu, S. C., Minton, N. P., Giaccia, A. J., & Brown, J. M. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301659 · Cited by 195

Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards

Ware, D. C., Palmer, B. D., Wilson, W. R., & Denny, W. A. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00065a006 · Cited by 194

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

Sun, J. D., Liu, Q., Wang, J., Ahluwalia, D., Ferraro, D. J., Wang, Y., Duan, J.-X., Ammons, W. S., Curd, J. G., Matteucci, M. D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1980 · Cited by 191

Preclinical studies and clinical correlation of the effect of alkylating dose.

Frei, E., Teicher, B. A., Holden, S. A., Cathcart, K. N. S., & Wang, Y. (1988) · PubMed · Cited by 188

Hypoxia Induces Escape from Innate Immunity in Cancer Cells via Increased Expression of ADAM10: Role of Nitric Oxide

Barsoum, I. B., Hamilton, T. K., Li, X., Cotechini, T., Miles, E. A., Siemens, D. R., & Graham, C. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2104 · Cited by 188

Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels

Harada, H., Inoue, M., Itasaka, S., Hirota, K., Morinibu, A., Shinomiya, K., Zeng, L., Ou, G., Zhu, Y., Yoshimura, M., et al. (2012) · Nature Communications · doi:10.1038/ncomms1786 · Cited by 183

HIF-1 and tumour radiosensitivity

Moeller, B. J., & Dewhirst, M. W. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603201 · Cited by 178

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia

Guise, C. P., Mowday, A. M., Ashoorzadeh, A., Yuan, R., Lin, W., Wu, D., Smaill, J. B., Patterson, A. V., & Ding, K. (2013) · 癌症：英文版 · doi:10.5732/cjc.012.10285 · Cited by 177

Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.

Fox, M. E., Lemmon, M. J., Mauchline, M. L., Davis, T. O., Giaccia, A. J., Minton, N. P., & Brown, J. M. (1996) · PubMed · Cited by 170

The role of hypoxia-activated prodrugs in cancer therapy

Denny, W. A. (2000) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00006-1 · Cited by 167

Hypoxia-regulated microRNAs in human cancer

Shen, G., Li, X., Jia, Y.-F., Piazza, G. A., & Xi, Y. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.195 · Cited by 164

Tumor-activated Prodrugs—A New Approach to Cancer Therapy

Denny, W. A. (2004) · Cancer Investigation · doi:10.1081/cnv-200027148 · Cited by 161

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Weiss, G. J., Infante, J. R., Chiorean, E. G., Borad, M. J., Bendell, J. C., Molina, J. R., Tibes, R., Ramanathan, R. K., Lewandowski, K., Jones, S. F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3425 · Cited by 159

New anticancer strategies targeting HIF-1

Yeo, E.-J., Chun, Y., & Park, J. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.02.040 · Cited by 158

Microenvironment and Radiation Therapy

Yoshimura, M., Itasaka, S., Harada, H., & Hiraoka, M. (2012) · BioMed Research International · doi:10.1155/2013/685308 · Cited by 155

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., & Ganjoo, K. N. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3660 · Cited by 155

Hypoxia and anemia: effects on tumor biology and treatment resistance

Vaupel, P. W., & Mayer, A. (2005) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2004.11.005 · Cited by 151

Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.

Harada, H., Hiraoka, M., & Kizaka‐Kondoh, S. (2002) · PubMed · Cited by 146

Oxygen Levels in Normal and Previously Irradiated Human Skin as Assessed by EF5 Binding

Evans, S. M., Schrlau, A. E., Chalian, A. A., Zhang, P., & Koch, C. J. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700451 · Cited by 137

Significance of HIF-1-active cells in angiogenesis and radioresistance

Harada, H., Kizaka‐Kondoh, S., Li, G., Itasaka, S., Shibuya, K., Inoue, M., & Hiraoka, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210556 · Cited by 136

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

Albertella, M. R., Loadman, P. M., Jones, P. H., Phillips, R. M., Rampling, R., Burnet, N. G., Alcock, C., Anthoney, A., Vjaters, E., Dunk, C. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4020 · Cited by 131

Tirapazamine: From Bench to Clinical Trials

Marcu, L. G., & Olver, I. (2006) · Current Clinical Pharmacology · doi:10.2174/157488406775268192 · Cited by 125

Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1

Doktorová, H., Hraběta, J., Khalil, M. A., & Eckschlager, T. (2015) · Biomedical Papers · doi:10.5507/bp.2015.025 · Cited by 122

Hypoxia-inducible factor 1–mediated characteristic features of cancer cells for tumor radioresistance

Harada, H. (2016) · Journal of Radiation Research · doi:10.1093/jrr/rrw012 · Cited by 116

Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile

Elia, A. R., Cappello, P., Puppo, M., Fraone, T., Vanni, C., Eva, A., Musso, T., Novelli, F., Varesio, L., & Giovarelli, M. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0208082 · Cited by 106

Clostridium spores as anti-tumour agents

Van Mellaert, L., Barbé, S., & Anné, J. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.02.002 · Cited by 101

Hypoxia-Activated Prodrugs in Cancer Therapy: Progress to the Clinic

Denny, W. A. (2010) · Future Oncology · doi:10.2217/fon.10.1 · Cited by 100

Progress toward Overcoming Hypoxia-Induced Resistance to Solid Tumor Therapy

Reginato, M., & Karakashev, S. (2015) · Cancer Management and Research · doi:10.2147/cmar.s58285 · Cited by 95

Physiologic Mechanisms of Therapeutic Resistance: Blood Flow and Hypoxia

Teicher, B. A. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30105-9 · Cited by 94

Suppression of Hypoxia-Inducible Factor 2α Restores p53 Activity via Hdm2 and Reverses Chemoresistance of Renal Carcinoma Cells

Roberts, A. M., Watson, I. R., Evans, A. J., Foster, D. A., Irwin, M. S., & Ohh, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1770 · Cited by 88

Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation

Brown, J. M., & Lemmon, M. J. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90057-b · Cited by 86

Hypoxia Inhibition of Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)

Park, S., Billiar, T. R., & Seol, D. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6421 · Cited by 76

Phase I and Pharmacologic Study of the Novel Indoloquinone Bioreductive Alkylating Cytotoxic Drug E09

Schellens, J. H. M., Planting, A. S. T., van Acker, B. A. C., Loos, W. J., de Boer-Dennert, M. M., van der Burg, M. E. L., Koier, I., Krediet, R. T., Stoter, G., & Verweij, J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.12.906 · Cited by 75

Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs)

Denny, W. A., & Wilson, W. R. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00689806 · Cited by 73

Hypoxia-Inducible Regulation of a Prodrug-Activating Enzyme for Tumor-Specific Gene Therapy

Shibata, T., Giaccia, A. J., & Brown, J. M. (2002) · Neoplasia · doi:10.1038/sj.neo.7900189 · Cited by 72

Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards

Wilson, W. R., Hicks, K. O., Pullen, S. M., Ferry, D. M., Helsby, N. A., & Patterson, A. V. (2007) · Radiation Research · doi:10.1667/rr0807.1 · Cited by 71

Targeting hypoxia at the forefront of anticancer immune responses

Noman, M. Z., & Chouaib, S. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954463 · Cited by 70

Tumour Hypoxia: Impact on Biology, Prognosis and Treatment of Solid Malignant Tumours

Weinmann, M., Belka, C., & Plaßwilm, L. (2004) · Oncology Research and Treatment · doi:10.1159/000075611 · Cited by 64

HIF-1α contributes to hypoxia-induced invasion and metastasis of esophageal carcinoma via inhibiting E-cadherin and promoting MMP-2 expression.

Jing, S., Wang, Y.-D., Kuroda, M., Su, J.-W., Sun, G.-G., Liu, Q., Cheng, Y.-J., & Yang, C.-R. (2012) · PubMed · doi:10.18926/amo/48964 · Cited by 61

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group

Dirix, L. Y., Tønnesen, F., Cassidy, J., Epelbaum, R., Huinink, W. W. T. B., Pavlidis, N., Sorio, R., Gamucci, T., Wolff, I., Velde, A. T., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00226-2 · Cited by 61

Hypoxia-Dependent Retinal Toxicity of Bioreductive Anticancer Prodrugs in Mice

Lee, A. E., & Wilson, W. R. (2000) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1999.8834 · Cited by 60

Targeting tumors with hypoxia-activated cytotoxins

Ahn, G. (2007) · Frontiers in bioscience · doi:10.2741/2329 · Cited by 58

Effects of Oxygen and Sulphydryl-containing Compounds on Irradiated Transforming DNA

Held, K. D., Harrop, H. A., & Michael, B. D. (1984) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553008414550881 · Cited by 56

Recent developments in the design of bioreductive drugs.

Denny, W. A., Wilson, W. R., & Hay, M. P. (1996) · Europe PMC (PubMed Central) · Cited by 54

Breast cancer angiogenesis — new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting

Harris, A. L., Zhang, H., Moghaddam, A., Fox, S., Scott, P. A. E., Pattison, A. J., Gatter, K. C., Stratford, I. J., & Bicknell, R. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01803788 · Cited by 54

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

Sun, J. D., Liu, Q., Ahluwalia, D., Li, W., Meng, F., Wang, Y., Bhupathi, D., Ruprell, A. S., & Hart, C. P. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2014.1003005 · Cited by 54

Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: Long-term results of a placebo-controlled randomised study

Karasawa, K., Sunamura, M., Okamoto, A., Nemoto, K., Matsuno, S., Nishimura, Y., & Shibamoto, Y. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.02.007 · Cited by 52

Hypoxia-specific gene expression for ischemic disease gene therapy

Kim, H., Mahato, R. I., & Lee, M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.009 · Cited by 48

AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: Results of an IAEA multicentre randomised trial

Dobrowsky, W., Huigol, N., Jayatilake, R., Kizilbash, N.-I.-A., Okkan, S., Kagiya, V. T., & Tatsuzaki, H. (2006) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2006.11.007 · Cited by 47

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling

Foehrenbacher, A., Secomb, T. W., Wilson, W. R., & Hicks, K. O. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00314 · Cited by 45

New antimetastatic hypoxic cell radiosensitizers: design, synthesis, and biological activities of 2-nitroimidazole-acetamide, TX-1877, and its analogues

Kasai, S., Nagasawa, H., Yamashita, M., Masui, M., Kuwasaka, H., Oshodani, T., Uto, Y., Inomata, T., Oka, S., Inayama, S., et al. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00265-0 · Cited by 45

Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells

Parliament, M. B., Wiebe, L., & Franko, A. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.418 · Cited by 31

Mechanism of hypoxia‐specific cytotoxicity of procaspase‐3 fused with a VHL‐mediated protein destruction motif of HIF‐1α containing Pro564

Harada, H., Kizaka‐Kondoh, S., & Hiraoka, M. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.09.025 · Cited by 31

Prolyl hydroxylase inhibitors act as agents to enhance the efficiency of cell therapy

Esfahani, M., Karimi, F., Afshar, S., Niknazar, S., Sohrabi, S., & Najafi, R. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1084281 · Cited by 20

The remarkable yin and yang of tumour hypoxia

Brown, M. (2010) · International Journal of Radiation Biology · doi:10.3109/09553002.2010.492492 · Cited by 18

Introduction of hypoxia-targeting p53 fusion protein for the selective therapy of non-small cell lung cancer

Zhao, Y. Q., Wu, S., Wu, J., Jia, P., Gao, S., Yan, X.-D., & Wang, Y. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.1.13960 · Cited by 17

Suicide gene therapy : methods and reviews

Springer, C. J. (2004) · Medical Entomology and Zoology · Cited by 13

Direct and indirect effects of ionizing radiations

Dale, W. M. (1966) · Handbuch der medizinischen Radiologie · doi:10.1007/978-3-642-99899-7_1 · Cited by 5

Cancer Hypoxia and the Tumour Microenvironment as Effectors of Cancer Metabolism

Armitage, E. G., Kotze, H. L., & Williams, K. J. (2014) · SpringerBriefs in systems biology · doi:10.1007/978-1-4939-0615-4_2 · Cited by 2

Untitled work

Santiago (2001) · doi:10.1002/1529-0131(200107)44:7

Phototherapy in cancer treatment: strategies and challenges

Cai, Y., Chai, T., Nguyen, W., Liu, J., Xiao, E., Ran, X., Ran, Y., Du, D., Chen, W., & Chen, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02140-y · Cited by 453

Cellular Stress Responses in Radiotherapy

Kim, W., Lee, S., Seo, D., Kim, D., Kim, K., Kim, E., Kang, J., Seong, K. M., Youn, H., & Youn, B. (2019) · Cells · doi:10.3390/cells8091105 · Cited by 370

Characterization of Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model

Huang, Z., Yu, P., & Tang, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s249756 · Cited by 242

Hypoxia and HIF Signaling: One Axis with Divergent Effects

Corrado, C., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165611 · Cited by 184

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy

Li, Y., Zhao, L., & Li, X.-F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700407 · Cited by 172

Target for tumor hypoxia

Jian, D. (2004) · Zhongguo aizheng zazhi

Tumor Hypoxia and Radioresistance

Morović, S. (2024) · Radiološki vjesnik · doi:10.55378/rv.48.2.6 · Cited by 3

A Review of the Role of Hypoxia in Radioresistance in Cancer Therapy

Bouleftour, W., Rowinski, E., Louati, S., Sotton, S., Wozny, A., Moreno-Acosta, P., Méry, B., Rodriguez‐Lafrasse, C., & Magné, N. (2021) · Medical Science Monitor · doi:10.12659/msm.934116 · Cited by 130

An Enhanced Scrutiny of Mechanistic and Translational Approaches to Extinguish Cancer Hypoxia

Radhakrishnan, A., Shanmukhan, N. K., & Linda Christabel, S. (2024) · Pharmaceutical Nanotechnology · doi:10.2174/0122117385328105241216042016

Tumor Hypoxia

Nordsmark, M., Busk, M., Petersen, J. B. B., Alsner, J., Overgaard, J., & Horsman, M. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-444-53632-7.00903-5